217 related articles for article (PubMed ID: 37577497)
1. A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma.
Achom M; Sadagopan A; Bao C; McBride F; Xu Q; Konda P; Tourdot RW; Li J; Nakhoul M; Gallant DS; Ahmed UA; O'Toole J; Freeman D; Mary Lee GS; Hecht JL; Kauffman EC; Einstein DJ; Choueiri TK; Zhang CZ; Viswanathan SR
bioRxiv; 2023 Aug; ():. PubMed ID: 37577497
[TBL] [Abstract][Full Text] [Related]
2. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
3. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
[TBL] [Abstract][Full Text] [Related]
5. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
6. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
8. Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma.
Shi Q; Liu N; Yang L; Chen Y; Lu Y; Guo H; Han X; Li D; Gan W
Cell Commun Signal; 2021 Nov; 19(1):114. PubMed ID: 34784933
[TBL] [Abstract][Full Text] [Related]
9. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
10. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
11. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
12. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
[TBL] [Abstract][Full Text] [Related]
13. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
[TBL] [Abstract][Full Text] [Related]
14. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
15. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
16. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
17. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
18. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
[TBL] [Abstract][Full Text] [Related]
20. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
